On 17 January 2018, orphan designation (EU/3/17/1961) was granted by the European Commission to Astellas Pharma Europe B.V., the Netherlands, for gilteritinib (also known as ASP2215) for the treatment of acute myeloid leukaemia.
Xospata for treatment of acute myeloid leukaemia has been authorised in the EU as Xospata since 2019.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;